Skip to main content
S&P 5007,625.30+0.97%DOW51,751.83+0.56%NASDAQ26,364.08+1.48%BTC$76,319.00+0.87%ETH$2,451.68+2.67%GOLD$4,397.10+0.22%OIL$100.93-1.46%
Smart Investors Daily
MG

NASDAQ · MGX

Metagenomi, Inc. Common Stock

Healthcare · Biotechnology

$1.15

Down-$0.00 (-0.43%)

Updated Sep 17, 2026, 3:20 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
65.71M
P/E ratio
-0.75
Dividend yield
0.00%
52-week range
$1.13 – $1.83
Volume
111K
Avg. volume
672.12K

Price performance

MGX price history

1M range · 20 trading sessions · Daily adjusted prices

MGX closed at $1.15 after 20 trading sessions, down 7.26% for the selected period.

Last close
$1.15
Period change
-7.26%
Period low
$1.15
Period high
$1.24
Daily close
View OHLC price history
MGX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$1.16$1.175$1.15$1.15111K
Sep 15, 2026$1.19$1.19$1.15$1.16160.37K
Sep 14, 2026$1.17$1.195$1.17$1.19157.86K
Sep 11, 2026$1.16$1.22$1.16$1.1654.3K
Sep 10, 2026$1.15$1.215$1.15$1.16471.79K
Sep 9, 2026$1.17$1.20$1.15$1.15147.56K
Sep 8, 2026$1.15$1.18$1.13$1.16293.71K
Sep 4, 2026$1.14$1.1702$1.14$1.1754.81K
Sep 3, 2026$1.203$1.21$1.15$1.1669.01K
Sep 2, 2026$1.16$1.19$1.15$1.16313.11K
Sep 1, 2026$1.19$1.19$1.1281$1.17239.77K
Aug 31, 2026$1.18$1.19$1.17$1.18106.86K
Aug 28, 2026$1.20$1.24$1.19$1.1978.13K
Aug 27, 2026$1.23$1.23$1.20$1.2172.67K
Aug 26, 2026$1.21$1.24$1.21$1.2259.57K
Aug 25, 2026$1.22$1.25$1.21$1.21124.88K
Aug 24, 2026$1.25$1.25$1.205$1.21211.24K
Aug 21, 2026$1.22$1.26$1.20$1.23303.2K
Aug 20, 2026$1.21$1.25$1.20$1.20107.02K
Aug 19, 2026$1.21$1.25$1.21$1.24248.13K

Latest MGX news

The latest Smart Investors Daily articles mentioning MGX.

Stock researchCompany · Overview

MGX research

Overview

Company profile and research snapshot.

Company profile

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.50
Implied upside
—
Analysts
—
MGX recent ratings
DateFirmRatingTarget
Aug 11, 2026Wells FargoOverweight—
Jul 7, 2026Chardan CapitalBuy—
May 12, 2026Wells FargoOverweight—
Aug 19, 2025HC Wainwright & Co.Buy—
Aug 15, 2025Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference, being held in Boston, MA, on Thursday, September 10, 2026, at

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By